David W. Miles, MB BS, BSc, MD, FRCP
Although chemotherapy remains the mainstay of treatment for patients with triple-negative breast cancer (TNBC), promising developments are unfolding on several fronts, including new ways of using existing therapies and the exploration of immunotherapy, novel antibodies, and agents targeting the PI3K/mTOR/AKT pathway. A paucity of biomarkers to predict for responders remains one of the most significant challenges impeding progress, according to David W. Miles, MB BS, BSc, MD, FRCP.
, LLC, Miles, a consultant medical oncologist at West Hertfordshire Hospitals in England, provided his perspective on potential new treatment options for patients with TNBC.
In everyday practice, treatment for patients with TNBC typically includes chemotherapy. “[For] those of us working out in the peripheral hospitals and seeing lots of patients, we are still stuck with chemotherapy,” said Miles. “We say to our patients, ‘I’m sorry the endocrine treatment isn’t going to work, I’m sorry HER2 isn’t a target, so we’re really going to hit as hard as we can with chemotherapy,’ even for those in relatively low-risk situations in the adjuvant setting.”
Table. Survival Rates of Combinations in the tnAcity Trial1
Miles noted that the trial was not progressing to phase III due to the evolving treatment landscape, but he suggested considering a platinum-containing regimen for these patients.
... to read the full story